<DOC>
	<DOCNO>NCT00001958</DOCNO>
	<brief_summary>This 12-month study evaluate safety effectiveness hydroxyurea treat beta-thalassemia , type anemia cause defective hemoglobin ( oxygen-carrying pigment blood ) . Hemoglobin compose two protein chains-alpha globin chain beta globin chain ; patient beta-thalassemia make beta globin . Patients often require frequent red blood cell transfusion . This lead iron overload , , turn , require iron chelation therapy ( removal iron blood ) . Some drug , include hydroxyurea , stimulate production third type protein chain call gamma chain . In womb , fetus make type protein instead beta globin . It birth , fetus longer produce gamma globin beta globin deficiency become apparent . Gamma chain synthesis improve hemoglobin red blood cell production , correct anemia . This study determine dose hydroxyurea treatment reduce patient ' need red blood cell transfusion whether certain factor might predict patient likely benefit treatment . Patients 15 year older moderately severe beta-thalassemia may eligible study . Participants take hydroxyurea daily dose calculated accord patient 's body size . Blood drawn weekly measure blood cell platelet count . The drug dosage may increase 12 week treatment 24 week white cell platelet count remain stable . Patients respond dramatically treatment may continue receive hydroxyurea 3 year .</brief_summary>
	<brief_title>Hydroxyurea Treat Beta-Thalassemia ( Cooley 's Anemia )</brief_title>
	<detailed_description>Individuals homozygous beta thalassemia either severely anemic dependent blood transfusion sustain life . Deficient synthesis beta chain lead imbalanced chain synthesis excess alpha globin . This alpha globin precipitate , cause ineffective erythropoiesis shorten red cell survival . Hydroxyurea cell-cycle specific agent block DNA synthesis inhibit ribonuclease reductase , enzyme convert ribonucleotides deoxyribonucleotides . Administration hydroxyurea primates 300 patient sickle cell anemia frequently , invariably associate substantial increase synthesis gamma globin . In patient homozygous beta-thalassemia , enhanced gamma globin synthesis could partially compensate deficient synthesis beta globin render chain synthesis balance reduce relative excess alpha chain . The purpose protocol test hypothesis chronic daily low dose administration hydroxyurea enhance gamma globin synthesis , increase red cell production partially substantially correct anemia patient homozygous beta-thalassemia . The effect treatment monitor serial determination hemoglobin hematocrit . The relationship response therapy specific beta-globin mutation ( ) also analyze . This study therefore examine cohort patient previously treat hydroxyurea .</detailed_description>
	<mesh_term>Thalassemia</mesh_term>
	<mesh_term>Hemoglobinopathies</mesh_term>
	<mesh_term>beta-Thalassemia</mesh_term>
	<mesh_term>Hydroxyurea</mesh_term>
	<criteria>BetaThalassemia Intermedia patient . Steadystate Hb value great 6.5gm/dl ( unrelated transfusion ) Males female . Patients great 15 year age . Patients transfusionrequiring dependent offer opportunity enroll . Stable renal hepatic function Willingness use appropriate birth control measure . Ability give inform consent . No betathalassemia major . No blood transfusion requirement great 1 unit every 2 month last 12 month . No patient WBC less 4000/micrograms . No one platelet count less 150,000/micrograms . No evidence active viral infective , include viral hepatitis . No abnormal liver function test ( ALT AST great 2.5 x normal ) . No abnormal renal function test ( creatinine great 1.5 mg/dl ) . No HIV positive blood test .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2002</verification_date>
	<keyword>Gamma Gene</keyword>
	<keyword>Hemoglobin Switching</keyword>
	<keyword>Erythropoiesis</keyword>
	<keyword>HbE Hemoglobin Chain Synthesis Imbalance</keyword>
	<keyword>Cooley 's Anemia</keyword>
	<keyword>Beta-Thalassemia Intermedia</keyword>
</DOC>